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Impact of Appropriate Pharmaceutical Therapy for
Chronic Conditions on Direct Medical Costs and
Workplace Productivity: A Review of the Literature
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ABSTRACT
This paper presents the findings of a literature review investigating the economic impact of
appropriate pharmaceutical therapy in treating four prevalent chronic conditions—asthma,
diabetes, heart failure, and migraine. The goal of the review was to identify high-quality stud-
ies examining the extent to which appropriate pharmaceutical therapy impacts overall med-
ical expenditure (direct costs) and workplace productivity (indirect costs). The working hy-
pothesis in conducting the review was that the costs of pharmaceuticals for the selected chronic
conditions are offset by savings in direct and indirect costs in other areas. The literature pro-
vides evidence that appropriate drug therapy improves the health status and quality of life
of individuals with chronic illnesses while reducing costs associated with utilization of emer-
gency room, inpatient, and other medical services. A growing body of evidence also suggests
that workers whose chronic conditions are effectively controlled with medications are more
productive. For employers, the evidence translates into potential direct and indirect cost sav-
ings. The findings also confirm the importance of pharmaceutical management as a corner-
stone of disease management. (Disease Management 2004;7:61–75)
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INTRODUCTION
ESCALATING HEALTH CARE COSTS are a signifi-cant concern for policy makers and for em-
ployers, who, in the United States, bear a sig-
nificant share of the total spending burden.1 In
response to this trend, employers have sought
ways to limit their health expenditure risks,
such as defined contribution plans, benefit 
reductions, increased out-of-pocket payments
(deductibles and co-payments), reduced choices
among plans and providers, and tiered benefit
plans. The pharmacy budget has been espe-
cially susceptible to these strategies. The po-
tential impact of having a “silo mentality,” in
which pharmacy benefit management deci-
sions are made without reference to the total
spending picture, has not been well studied.
Chronic conditions represent a public health
issue of magnitude. While some conditions af-
fect individuals of all ages, the prevalence for
many increases with age. With the average age
in the United States climbing, the prevalence 
of chronic conditions is expected to increase
rapidly over the coming decade.
Evidence-based treatment guidelines and
Jefferson Medical College, Philadelphia, Pennsylvania.
disease management programs for many
chronic conditions emphasize appropriate
pharmacotherapy as the cornerstone to im-
proving health outcomes and controlling costs.
Numerous studies have shown that appropri-
ate medications for chronic conditions reduce
symptoms and prevent or delay the onset of
complications, resulting in improved health-re-
lated quality of life and workplace productiv-
ity.2 This paper reports on a review of the lit-
erature examining cost impact of appropriate
pharmaceutical care for selected chronic con-
ditions.
OBJECTIVE
The working hypothesis of this review was
that the cost of providing health insurance cov-
erage that includes pharmaceutical treatment
for chronic conditions potentially could be off-
set by the cost savings associated with de-
creased medical costs and work loss. We con-
ducted a review of the literature describing the
impact of appropriate medication use on costs
of care, from an employer perspective. Two
main categories of costs—direct medical costs as-
sociated with health care service utilization, and
indirect costs associated with losses to workplace
productivity—were examined. While other costs
may be associated to different degrees with the
studied conditions, this review was limited to the
two categories of cost of greatest interest to em-
ployers. Workplace productivity was defined to
include both absenteeism—missed days from
work due to illness—and presenteeism—re-
duced output or performance for employees
who present for work despite illness.
METHODS
Four chronic conditions—asthma, migraine,
diabetes, and heart failure—were selected for
review, based on their prevalence, costs, and
relevance to employers, as well as the use of
appropriate pharmacotherapy as a cornerstone
of the management of each disease. A literature
search, using the MEDLINE database, covering
the time period between 1993 and 2003, was
conducted to identify published studies in the
peer-reviewed literature examining the impact
of appropriate pharmaceutical agents on health
care utilization and workplace productivity.
Each identified manuscript was reviewed and
evaluated on the basis of the following: (1)
study design and methods, (2) study popula-
tion, (3) class and name of drug(s) studied, (4)
type(s) of health care use studied, (5) types of
workplace productivity studied, (6) impact of
therapy on health care use and costs, and (7)
impact of therapy on workplace productivity.
Reference lists of key publications were re-
viewed to identify other relevant articles,
which, in turn, were obtained and reviewed.
RESULTS
The results of the literature review for each
of the four chronic conditions examined are
presented, including overviews of the epi-
demiology of the conditions and associated
costs and summaries of the evidence of the im-
pact of pharmaceuticals on direct and indirect
costs.
Asthma
Asthma is one of the most prominent public
health issues in children and adults.3,4 In the
United States, asthma affects approximately 15
million individuals3 and is the most common
illness in children and adolescents.5 On an an-
nual basis, 5,000 deaths, 500,000 hospitaliza-
tions, and 2 million emergency department
(ED) visits are attributed to asthma.6–8 Fur-
thermore, asthma has been estimated to cause
14 million school absence days and 14.5 million
work absence days annually.6 Accordingly,
health care costs are substantial and were esti-
mated to be $12.7 billion in 1998.7,9 The aver-
age annual cost per patient has been estimated
at $1,238.10
The majority of asthma-related costs (58%)
are related to direct medical care expenditures,
of which 45% are associated with hospitaliza-
tions, outpatient hospital visits, and ED visits
and 43% with prescription medications.9 How-
ever, indirect costs—which include non-med-
ical economic losses such as days missed from
work and school, caregivers’ costs, premature
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retirement, and death—represent 42% of the to-
tal health care expenses for the disease.9
Pharmacological therapy, along with patient
education, control of asthma triggers, and the
monitoring of asthma severity with objective
measures of lung function, plays a central role
in the National Heart, Blood, and Lung Insti-
tute’s (NHBLI’s) asthma treatment guidelines.3
Despite these guidelines, the current use of con-
troller medications is seriously suboptimal.11–13
Long-term-control medications, used to prevent
and control disease symptoms while simultane-
ously reducing the frequency and severity of
asthma,3 include inhaled and systemic cortico-
steroids, cromolyn sodium and nedocromil,
long-acting beta2-agonists, methylxanthines,
and leukotriene modifiers. Although inhaled
corticosteroids are universally considered the
most effective controllers and recommended as
first-line therapy3,4 recent evidence from clinical
trials indicates that the synergic association of
beta2-agonists and corticosteroids might be ben-
eficial for more effective long-term treatment,
leading to improvements in lung function and
symptoms, as well as a decreased need for rapid
relief, short-acting medications.3,4,14 As a result,
the 2002 updated NHBLI asthma guidelines rec-
ommend that the preferred treatment for pa-
tients with moderate to severe asthma be the ad-
dition of long-acting inhaled beta2-agonists to
low-to-medium doses of corticosteroids.15
Impact of asthma drug therapy on health care uti-
lization and direct costs. Several studies have
documented an association between the in-
creased use of inhaled corticosteroids among
patients with asthma and a decrease in utiliza-
tion of costly health care resources, namely,
hospitalizations16–19 and ED visits.20 One large
population-based study21 showed that the use
of inhaled steroids was associated with a 50%
decrease in risk of hospitalization. A recent re-
view16 suggested that regular use of inhaled
corticosteroids can decrease asthma hospital-
izations by up to 80%. A large retrospective
study of acute hospitalization among 6 million
people in Sweden between 1978 and 199118
showed that increased sales of inhaled corti-
costeroids were significantly related to a down-
ward trend in the total number of bed-days re-
lated to asthma.
Studies investigating the relative risk of re-
turn visits to the ED among users and nonusers
of inhaled corticosteroids indicate that patients
who use inhaled corticosteroids following dis-
charge from the ED have a significantly lower
risk of subsequent ED visits22 and that inhaled
corticosteroid therapy can reduce the risk of 
rehospitalization among elderly asthmatics.23
Perhaps most important is the finding that the
regular use of inhaled corticosteroids is asso-
ciated with a decrease in asthma mortality
rates.24,25
Studies consistently show that proper ad-
herence to national asthma guidelines is asso-
ciated with better clinical outcomes, lower
health care utilization,11 and lower total health
care costs,26 while poor adherence to thera-
peutic regimens is associated with excess
health care utilization and costs.27,28 A study of
adults with persistent asthma in France29 found
that poorly controlled asthma was associated
with a 2.5-fold increase in utilization costs,
compared with well-controlled asthma. An-
other study30 showed that the mean medica-
tion cost of patients whose medication use was
at variance with treatment guidelines was dou-
ble that of other asthma patients ($89 vs. $42),
and the mean total health care cost of the
non–guideline-compliant patients was almost
three times that of other asthma patients ($496
vs. $182). A study in the Medicaid population26
found that patients being treated with corti-
costeroids had lower total health care costs (by
24%) than patients without. These results are
consistent with asthma cost-effectiveness mod-
els, which suggest that the use of inhaled cor-
ticosteroids in adults with mild to moderate
asthma can decrease costs and improve qual-
ity of life.31
The impact of asthma on workplace productivity.
A number of studies document the deleterious
effects of asthma on quality of life and work
productivity.32–38 Recent results from the 2000
Behavioral Risk Factor Surveillance System
(using data from 163,773 respondents) indicate
that adult asthmatics have significantly more
physically unhealthy days, mentally unhealthy
days, and days with activity limitation com-
pared with adults without asthma.39
The impact of asthma on work-related im-
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pairment could be substantial. One population-
based study38 found that nearly a quarter of
working asthmatics changed their job or duties
because of their condition, another quarter re-
ported missing at least one partial or complete
work day in the last four weeks because of their
asthma, and almost one-fifth rated their effec-
tiveness on the job as less than or equal to 90%
in the last four weeks. Similar findings were re-
ported by Ungar and Coyte,32 who noted that
most productivity loss among asthmatic pa-
tients results from restricted days rather than
complete absenteeism. In light of the high rates
of absenteeism to begin with, this additional
cost to work productivity should be of special
concern to employers.
Missed work and restricted days affect em-
ployees with asthma, as well as employees who
have children with asthma. One study docu-
mented that among full-time working parents
of children with asthma, 39% of parents whose
children awakened one to three times, and 69%
of parents whose children awakened four to
seven times within a month’s period, missed at
least one day of work in that month.35 In an ef-
fort to estimate the patient-level costs of asthma
care to children, Ungar and Coyte37 found that
the indirect costs associated with parent pro-
ductivity loss were 12% of the total health care
costs, and almost half of the cost of medication,
which accounted for 31% of the total. Given
these facts, it is not surprising that, in one of
the first studies to estimate the expense of
asthma for a major U.S. employer,33 asthma
wage-replacement costs due to absenteeism
and disability (40%) accounted for almost as
much as those due to direct medical care (43%).
Undertreatment of asthma can lead to higher
direct medical costs as well as substantial indi-
rect costs to employers, through absenteeism,
impaired productivity and the ramifications of
decreased quality of life among employees.40
Conversely, asthma patients with better asthma
control have been shown to have lower health
care costs, less work impairment, and a better
quality of life.41 An increasing number of stud-
ies demonstrate that appropriate pharmacother-
apy within the context of comprehensive asthma
disease management programs can improve
clinical outcomes, cost outcomes, and work pro-
ductivity.42,43 Knoell et al44 demonstrated that
patient adherence to medication guidelines led
to improved work productivity. Similarly, out-
comes of a population-based asthma manage-
ment program showed an increase in quality of
life, as well as a decrease in absenteeism for those
who attended the program.45
The estimated cost savings to managed care
organizations or employers who participate in
asthma disease management programs can be
substantial. For example, results from the
Asthma Self-Management Program (ASMP)
demonstrated that the estimated cost savings
due to a reduction in the utilization of health care
services were $175,317. Since the cost of partici-
pating in the program was $49,500, participating
organizations yielded a net savings of $125,817,
or a return on investment of 254%.46 One asthma
intervention program, which trained providers
to follow national asthma guidelines, estimated
that the annual resource savings after the inter-
vention amounted to $4,845 per patient.47
Diabetes
In 2001, approximately 16.7 million adults in
the United States were thought to have dia-
betes, and 7.9% of adults were diagnosed with
the disease.48 The number of individuals with
diabetes is expected to continue to increase, ris-
ing to almost 22 million by 2025.49 These indi-
viduals are at greater risk for neurological, pe-
ripheral vascular, cardiovascular, renal, and
ophthalmic diseases than the non-diabetic 
population.50–53 In 2002 the total direct and in-
direct costs attributable to diabetes were esti-
mated to be $132 billion, averaging approxi-
mately $10,900 per diabetic.50 This review
focuses primarily on type 2 diabetes, which ac-
counts for 90% or more of all cases of dia-
betes.54,55 Although type 2 diabetes is often
asymptomatic in its early stages, as it progresses,
it frequently results in serious long-term com-
plications56–58 and lower quality of life.59–61
The American Diabetes Association (ADA)
treatment guidelines for type 2 diabetes focus
on maintenance of glycemic control and screen-
ing for and attempting to prevent the onset or
progression of complications.57 Other treat-
ment approaches can include collaboration be-
tween health practitioners and patients,62,63
and disease management, which has been as-
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sociated with significant reductions in health
care cost and use.64,65 While recommended
treatment strategies for type 2 diabetes vary by
individual case, at initial diagnosis they fre-
quently include some combination of diet and
exercise.57 As the disease progresses, for the
majority of patients non-pharmacological in-
terventions alone become insufficient to keep
blood glucose levels within target ranges, often
leading to the introduction of oral medica-
tions—alone, in combination, or together with
insulin.66 However, patient compliance with
treatment guidelines and preventive care stan-
dards has been shown to be less than optimal,
especially in cases with more complicated
treatment regimens.67–70 According to longitu-
dinal study data, the number of patients who
are able to maintain glycemic control using
only one medication also decreases over time,
and 50% in three years and 75% in nine years
need multiple therapies to remain within ac-
ceptable levels.66 Medications to address com-
plications are also frequently an important part
of the treatment regimen.57
Impact of diabetes drug therapy on health care
utilization and direct costs. Diabetes and its com-
plications have substantial impacts on health
care utilization.50,71–79 According to 2002 data
from the ADA, the estimated ratio of annual
per capita medical expenditures for individu-
als with and without diabetes was approxi-
mately 5:1 ($13,243 vs. $2,560, respectively).50
Previous studies support the findings that pa-
tients with type 2 diabetes have noticeably
higher medical costs than similar patients with-
out diabetes.73,77
Brown et al74 assessed medical costs attrib-
utable to the progression of cardiovascular
and renal disease in patients with type 2 dia-
betes and found that an individual’s medical
costs increased from baseline by 50%–360% for
cardiovascular disease and by 65%–771% for
renal disease, both depending on the stage of
the disease. The authors emphasized the role
of aggressive therapeutic treatments in lower-
ing costs through a reduction in microvascu-
lar and marcovascular complications. Caro et
al75 estimated the average direct costs of dia-
betes-related complications would amount to
more than $47,000 per person over 30 years of
age. In their model, the major contributors to
these costs included macrovascular diseases
(52% of total), nephropathy (21%), neuropathy
(17%), and retinopathy (10%).75 However,
they noted that the ability to translate a re-
duction in the risk of complications into cost
savings depends on the cost of the treatment
involved.
The direct medical costs of diabetes are often
determined by examining a variety of health
care expenditures, including but not limited 
to hospitalization, medication, nursing home, 
and physician costs.71,79–83 Estimates of the di-
rect medical costs of diabetes have increased
rapidly over the past few years.50,71 Among the
factors contributing to the direct costs of dia-
betes overall, inpatient health care utilization
consumes the largest portion (greater than
60%) of total health care expenditures.71,79 In
1997, the direct medical costs for diabetes were
estimated at $44.1 billion.71 A 2002 study more
than doubles this figure, estimating direct costs
at $91.8 billion.50
Medication costs have been found to con-
tribute less than 10% of total health care ex-
penditures related to diabetes,79 though costs
may increase significantly over time, with the
onset of major complications.73 However, lim-
ited research exists on the specific impact of
medications on direct costs associated with the
disease. In a treatment simulation model, pa-
tients who used oral medications and achieved
glycemic control, as defined in the model, were
found to have average annual costs $422 lower
than those patients who did not achieve con-
trol.84 An economic analysis as part of a ran-
domized controlled clinical trial showed that
intensive glycemic control was a cost-effective
means of delaying the onset of complications,
with a cost reduction of $1,862 associated with
each year spent free of complications.85 The av-
erage total cost per patient of standard medical
practice has been estimated to decrease by ap-
proximately $438 with use of an oral medica-
tion (metformin), compared with conventional
treatment (primarily diet).86 And a study that
investigated the impact of various treatment
methods on total direct costs found that treat-
ment with a class of oral medications—sul-
fonylureas—lowered the annual costs over no
treatment by $213.87
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The impact of diabetes on workplace productiv-
ity. Significantly fewer studies have been con-
ducted to investigate the indirect costs of dia-
betes and type 2 diabetes in particular.50,71,82,88
Although not specific to type 2 diabetes, a num-
ber of studies have assessed the economic im-
plications of work disability and productivity
losses for individuals with all types of dia-
betes.71,89–93 In particular, work disability,
whether measured in days or in quarters, has
been shown to be substantially impacted by di-
abetes.50,90,92,93 In 2002, indirect costs attribut-
able to diabetes in general, as measured by 
restricted or lost work, premature mortality,
and permanent disability, were quantified as
$10,759, $21,558, and $7,494 billion, respec-
tively—amounting to $39,810 billion in total in-
direct costs.50
Relatively recent results from an evaluation
of the health economic benefit of improvement
in glycemic control in patients with type 2 di-
abetes point to significantly favorable health
economic outcomes in the form of higher re-
tained employment, greater productive capac-
ity, decreased absenteeism, fewer bed-days,
and fewer restricted-activity days.88 The sav-
ings realized in the study were $304 per 1,000
person days for bed-days and $1,615 per 1,000
person days for restricted activity days. It has
also been shown that diabetes medication in
general contributes to large savings in terms of
work days for employees with the disease, with
an average of 16 days saved because of treat-
ment, taking compliance rates into account.91
This translates into a net savings to employers
of $1,475, in 1996 dollars. Additionally, indi-
viduals on blood glucose-lowering agents who
are able to achieve better glycemic control have
been demonstrated to have fewer physical
symptoms and enhanced well-being,94 as well
as having a significantly reduced risk of hav-
ing cardiovascular and microvascular compli-
cations,95,96 although the risks of hypoglycemia
must be balanced against the benefits of tight
control.57
Evidence points to the value of early inter-
vention and tight glycemic control in helping to
delay or reduce the long-term consequences of
diabetes, and significant research has been aimed
at describing and identifying interventions that
could accomplish these goals.81,84,89,97,98 Because
the cost of complications may greatly increase
the costs of health care utilization for individu-
als with diabetes,73 one focus of interventions is
on the prevention and management of such com-
plications. Research has suggested that inter-
ventions aimed at preventing one individual’s
complications related to renal disease would re-
sult in total economic savings of $60,000 over
three years.81 In the management of type 2 dia-
betes and in the avoidance of complications lead-
ing to both direct and indirect costs, oral med-
ications play an integral part.97,98
Heart failure
The lifetime risk of developing heart failure
for both men and women has been estimated
at 20% (1 in 5).99 While heart failure is most
prevalent in people over the age of 65 years,
prevalence in the 55–64 year age range is 3%
for women and 5% for men.100 Risk factors as-
sociated with early onset of heart failure (such
as obesity, high blood cholesterol, and hyper-
tension) are on the rise in working adults
(35–64 years old), raising concerns of increased
incidence of heart failure in younger people.
The total direct costs of heart failure are pre-
dicted to exceed $22.1 billion in 2003.101 While
total costs include the costs of hospitalizations,
physicians’ office visits, nursing home stays,
home health care, and pharmacotherapy,101 the
main cost drivers are frequent hospitalizations
and readmissions.102 Readmission costs ac-
count for almost 30% of total inpatient care
costs.103
In his discourse on the economic burden of
heart failure, O’Connell104 estimates that “ . . .
if pharmacologic and behavioral approaches
were combined (in the management of the con-
dition), the five-year mortality rate could be re-
duced by as much as 50 percent.” There is no
cure for heart failure. The goals of treatment
are to relieve symptoms, enhance functional ca-
pacity, and improve survival, while reducing
costs related to hospitalizations.105
Impact of heart failure drug therapy on health
care utilization and direct costs.  Reducing the rate
of hospitalization and readmission is recog-
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nized as the key to decreasing the cost of care
for heart failure.106–109 Multiple clinical trials
suggest that use of appropriate drug therapies
may be the most effective way to reduce the
cost of care while reducing morbidity and mor-
tality: Drug therapies can reduce hospital-
ization from 12% to 35%, depending on the
agent.110–112 Drugs like angiotensin converting
enzyme (ACE) inhibitors and beta blockers
have proved not only to slow the pathophysi-
ological processes involved in heart failure, re-
lieve symptoms, and improve survival, but also
to reduce hospital days and readmissions in all
stages of heart failure.113–125 In fact, ACE in-
hibitors, beta blockers, diuretics, and digoxin
have recently been recommended as first-line
pharmacotherapy for heart failure by the
American College of Cardiology and the Amer-
ican Heart Association.115
ACE inhibitors have demonstrated a poten-
tial net savings of $36 million due to reduction
in hospitalization.113,126 For instance, the ACE
inhibitor ramipril has been shown to decrease
heart failure hospitalizations by 12%.111 The
SOLVD trial demonstrated that the enalapril
group had a 26% reduction in the risk of death
or hospitalization for worsening heart failure
compared with the placebo group.127 One cost
consequence analysis, based on clinical trial re-
sults,128 has shown that use of the ACE inhibitor
fosinopril achieved an overall cost savings of $1.6
million per 1,000 patients.129,130 Another study,
a cost-effectiveness analysis of the ACE inhibitor
captopril for heart failure patients, using SAVE
data, found that use of captopril therapy resulted
in a cost per life year saved of $1,460.131
The literature also contains a number of
compelling studies describing the impact of
beta-blocker therapy on utilization, overall
medical costs, and survival of patients with
heart failure. Clinical trials have demon-
strated that carvedilol therapy reduced mor-
tality by 65% and hospital admissions by 22%,
and reduced overall costs of care by approxi-
mately $14,530.132–134 A study using data from
the US Carvedilol Heart Failure Trials Program
has also shown that carvedilol reduced the risk
of hospitalization for any reason by 29%, the
risk of cardiovascular hospitalization by 28%,
the risk of heart failure hospitalization by 38%,
and the mean number of hospitalizations for
heart failure by 53%.135 These studies have also
documented that the cost per life-year saved
for carvedilol was $29,477 under limited bene-
fits assumptions and $12,799 under extended
benefits assumptions.136 A number of other
studies have similarly demonstrated the effec-
tiveness of beta-blockers carvedilol and biso-
prolol in reducing the rate of hospitalization
and the cost of care.120,133,137–139
A common problem in the care for patients
with heart failure is the underprescription and
underuse of appropriate drugs such as ACE in-
hibitors and beta blockers.140–144 For instance,
only slightly more than 50% of heart failure 
patients receive ACE inhibitor therapy, while
patients at all levels of severity should be re-
ceiving it.144 Therefore, an objective of cardio-
vascular quality improvement and disease
management programs should be to increase
the use of such life-saving and cost-effective
treatment regimens.
The impact of heart failure on workplace produc-
tivity. The published literature on the impact of
heart failure on workplace productivity is lim-
ited. This may be attributable in part to the 
relatively new science of productivity mea-
surement, and to the significantly higher preva-
lence of diagnosed heart failure in the older,
non-working population. In a 2001 report145
the National Committee for Quality Assurance
(NCQA) applied its economic model to esti-
mate the number of working people with heart
disease who are enrolled in health plans that
provide Health Plan Employer Data and Infor-
mation Set (HEDIS®) data (also see http://
www.ncqa.org). The NCQA compared the in-
direct costs associated with heart failure for its
accredited health plans (that is, health plans
that meet minimum treatment standards for
heart disease) and non-accredited health plans.
They reported that, for a population of
1,248,304 workers with heart disease (based on
prevalence data), a total of 2,917,000 missed or
unproductive workdays were avoided and
$501,000,000 in sick-day wages was saved by
the accredited health plans that provided the
appropriate outpatient treatments for patients
diagnosed with heart disease.145
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Migraine
Migraine headache is a highly prevalent146
chronic condition, which manifests as acute
episodes. Migraine is frequently misdiag-
nosed147 and undertreated.148 The prevalence of
migraine headache is three times as high for
women as it is for men (18% vs. 6%).149 The high-
est prevalence of migraine occurs between ages
25 and 44 years, a time when many women are
highly productive in their professional career,
family responsibilities, and social life.149
The direct and indirect costs of migraine head-
ache in the United States are significant. In 1994,
the associated health care costs for migraine
headache were approximately $1 billion.150 Es-
timates range from $17 billion in 1986 to $13 bil-
lion in 1994 for annual losses associated with lost
workplace productivity secondary to migraine
headache.150,151 A 1998 survey comparing pa-
tients with and without migraine found that
over a 6-month period, patients with migraine
had higher direct medical costs (by $107), due
largely to greater frequency of physician and ED
visits, and greater lost productivity, for a total
incremental 6-month cost of migraine of $313.152
Another study estimated the annual employer
cost of migraine associated with lost productiv-
ity at $3,309 per migraine.153
Fortunately, significant advances have been
made in migraine pharmacotherapy, with the
availability of the triptans, a class of drugs in-
troduced in the 1990s. A large number of stud-
ies have demonstrated improvement in pa-
tients’ health-related quality of life154–161 and
reductions in patients’ lost workplace pro-
ductivity associated with initiation of triptan
therapy.155–157,162–164 These improvements are
clearly of importance to the individual with 
migraine headaches. However, employers and
health care purchasers would be interested in
knowing whether the benefit(s) of a migraine-
specific medication (ie, decreased medical
costs, decreased lost workplace productivity)
are greater than its associated costs, thus po-
tentially offsetting the cost of migraine therapy
and producing a net benefit from the em-
ployer’s economic perspective.
Impact of migraine drug therapy on health care
utilization and direct costs. A recent literature re-
view by Caro and Getsios165 demonstrates that
a large number of investigations have exam-
ined the impact of triptan therapy on health
care use and the associated direct costs of in-
dividuals with migraine headache. Most of
these studies specifically evaluated sumatrip-
tan, the first commercially available triptan,
and a widely used migraine pharmacotherapy,
although several other triptans have since be-
come available. The majority of investigations
have demonstrated that sumatriptan therapy 
is associated with reductions in health care use.
For example, a prospective, observational
study examining the change in health care use
of 178 patients with migraine in a managed care
organization found significant decreases in the
mean number of physician office visits, ED vis-
its, and medical procedures in the six months
after sumatriptan therapy was initiated.166 Be-
cause the triptans are more expensive than tra-
ditional non-triptan therapies, some studies
have indicated that net direct medical costs
may increase following initiation of triptan
therapy. However, these studies generally have
not considered the non-medical and indirect
cost savings associated with improvement in
appropriate management, and reduction in
medical utilization.
The impact of migraine on workplace productiv-
ity.Many studies have demonstrated that trip-
tan therapy is associated with reductions in
time lost from work and non-work activities,
and their associated indirect costs.165 In an in-
vestigation examining the differences in time
lost from work and non-work activity before
and after the initiation of sumatriptan therapy,
Lofland et al166 showed that, on average, the
number of workdays missed due to migraine
decreased by 0.5 days and 0.7 days in the three
and six months, respectively, after starting
sumatriptan. In addition, individuals reported
working on average four days with migraine
symptoms in the three months before starting
sumatriptan, but six months after the initiation
of sumatriptan this had decreased to two days.
A cost-effectiveness and cost-benefit analysis of
data from this study167 showed an overall net
cost savings after sumatriptan therapy initia-
tion of $1,249, and an incremental cost-effec-
tiveness ratio of $25 for each additional mi-
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graine-disability-day avoided. Biddle et al168
demonstrated through a decision tree analysis
an annual incremental net benefit of sumatrip-
tan over usual therapy of $114–$540 per pa-
tient, with the higher costs of sumatriptan (in
comparison with usual therapy) being offset by
reductions in health care use and lost produc-
tivity. Other researchers, including Caro et
al,169 have demonstrated similar net savings.
DISCUSSION
Four chronic conditions were considered in
this literature review, which sought to sum-
marize key published studies on the epidemi-
ology and economic impact of these conditions,
with a focus on the economic impact of phar-
macotherapy on total direct medical cost and
workplace productivity. Care guidelines for
asthma, diabetes, heart failure, and migraine all
emphasize the critical role of pharmaceuticals
in managing these conditions. This review pro-
vides support for the role of pharmaceuticals
in managing clinical, humanistic, and economic
outcomes.
These findings may be helpful to employers
who are considering offering a pharmacy bene-
fit or restructuring existing benefits. This review
did not investigate the extent to which different
levels of benefits (eg, tiered benefits with differ-
ent levels of co-payments) foster or impede the
likelihood that patients will be prescribed ap-
propriate therapy, and will fill prescriptions and
adhere to provider recommendations. However,
we do demonstrate that the literature suggests
a consistent benefit to employers—in regard to
both direct medical cost savings and avoided
losses to workplace productivity—in making
appropriate pharmacotherapy available to em-
ployees (at least for these four prevalent and
costly chronic conditions).
The findings are limited to published stud-
ies. It is possible that “publication bias,” in
which only findings in favor of certain med-
ications get published, overestimates the con-
tribution of pharmacotherapy to cost manage-
ment for the four conditions studied. This
review also focused on key studies with mea-
surement of economic outcomes; it is possible
that some relevant studies either were not iden-
tified through this review or that economic data
in contrast with the findings cited above were
not included in the review. However, all rele-
vant identified articles, whether they sup-
ported or refuted the hypothesis of the eco-
nomic benefit of appropriate pharmacotherapy,
were reviewed and are cited as appropriate.
The focus of this review also was on the appro-
priate use of pharmacotherapy. Real world ef-
fectiveness and cost-effectiveness may be mit-
igated by patient adherence and other factors
that may be encountered less frequently in the
research environment. The cost savings associ-
ated with appropriate pharmaceutical use also
are sensitive to changes in drug pricing. Fur-
thermore, few of the studies discussed exam-
ined utilization and costs in the long term, be-
yond one or two years. Despite these concerns,
a large majority of published evidence makes
a compelling case for the potential economic
benefit of appropriate pharmacotherapy in ac-
cordance with current care guidelines.
Finally, much research remains to be done to
better establish the linkages between pharma-
cotherapy and workplace productivity. The 
science of productivity measurement is still de-
veloping, and controversy about which ap-
proach is most appropriate (eg, human capital,
friction cost, or other approaches) continues.
Measurement of presenteeism also is a devel-
oping field. The early evidence identified in
this literature review suggests direct relation-
ships between appropriate drug use and work-
place productivity, but additional high-quality
studies are needed.
CONCLUSIONS
The findings of this review strengthen the ar-
guments for appropriate pharmacotherapy as
a cornerstone for disease management efforts.
Employers should be concerned with ensuring
that employees have access to needed medica-
tions, and are educated and supported so as 
to be adherent to provider recommendations.
Appropriate pharmaceutical agents help to
counter the detrimental effects of chronic con-
ditions on patients, thereby improving health
status, reducing utilization of higher cost
health care resources, and decreasing time lost
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from workplace productivity. The evidence
suggests that increased costs for disease-spe-
cific pharmaceutical therapy, in accordance
with current care guidelines, may be offset by
savings in a combination of direct and indirect
medical costs.
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